

## Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda.

\*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Transfusion-related complications pose significant challenges in the management of children with severe malaria, HIV infection, and underlying hematological disorders. This comprehensive review examines the epidemiology, pathophysiology, clinical manifestations, and management strategies for transfusion-related complications in pediatric patients with these conditions. We explore the interplay between severe malaria, HIV, and underlying hematological disorders, highlighting the complexities encountered in clinical practice. Additionally, we discuss strategies for mitigating transfusion-related risks and optimizing patient outcomes. By synthesizing current evidence and clinical insights, this review provides a comprehensive understanding of transfusion-related complications in children with severe malaria, HIV, and underlying hematological disorders, aiming to inform and guide healthcare providers in their management of this vulnerable population.

**Keywords:** *Transfusion, complications, severe malaria, HIV, pediatric, hematological disorders, safety, management*

### Introduction

Blood transfusion is a critical therapeutic intervention frequently employed in the management of pediatric patients with severe malaria, HIV infection, and underlying hematological disorders.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. Elite Journal of Medical Sciences, 2024; 2(4):1-20

Severe malaria remains a leading cause of morbidity and mortality among children worldwide, particularly in regions with high transmission rates of *Plasmodium falciparum*. Concurrently, pediatric HIV infection poses significant challenges, with an estimated 1.7 million children under 15 years of age living with HIV globally. Moreover, children with underlying hematological disorders such as sickle cell disease, thalassemia, and bone marrow failure syndromes may require frequent transfusions to manage anemia and associated complications. The interplay between severe malaria, HIV infection, and underlying hematological disorders complicates the clinical management of pediatric patients, particularly concerning transfusion-related complications. Transfusion-transmitted infections, hemolytic reactions, and fluid overload are among the potential risks associated with blood transfusion in this population. These complications can lead to increased morbidity and mortality, emphasizing the importance of understanding their epidemiology, pathophysiology, and clinical manifestations to optimize patient care. Despite advances in transfusion medicine, several challenges persist in managing transfusion-related complications in pediatric patients with severe malaria, HIV infection, and underlying hematological disorders. Limited access to safe blood products, inadequate healthcare infrastructure, and resource constraints in low-resource settings hinder optimal transfusion practices. Additionally, the complex pathophysiological interactions between severe malaria, HIV infection, and hematological disorders necessitate tailored approaches to transfusion therapy, further complicating clinical decision-making.<sup>1-40</sup>

This review aims to provide a comprehensive overview of transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders. By synthesizing current evidence and clinical insights, we seek to elucidate the complexities of transfusion therapy in this vulnerable population and highlight strategies for mitigating transfusion-related risks. Ultimately, enhancing our understanding of transfusion-related complications in pediatric patients with severe malaria, HIV infection, and underlying hematological disorders is crucial for improving transfusion practices and optimizing patient outcomes.

## **Epidemiology and Pathophysiology**

The epidemiology of transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders is influenced by various factors, including disease prevalence, blood screening practices, and transfusion protocols. In regions with high malaria and HIV prevalence, the risk of transfusion-transmitted infections (TTIs), including HIV, hepatitis B and C, and malaria, is heightened. Children with severe malaria and HIV infection may require frequent transfusions due to anemia and associated complications, increasing their exposure to potential bloodborne pathogens. Furthermore, pediatric patients with underlying hematological disorders, such as sickle cell disease, thalassemia, and bone marrow failure syndromes, are also at increased risk of transfusion-related complications. Chronic transfusion therapy is often necessary to manage anemia and prevent complications such as stroke and vaso-occlusive crises in these patients. However, repeated transfusions can lead to iron overload,

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. Elite Journal of Medical Sciences, 2024; 2(4):1-20

alloimmunization, and other adverse effects, necessitating careful monitoring and management.<sup>41-60</sup>

The pathophysiology of transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders is multifactorial. Transfusion-transmitted infections (TTIs) occur when contaminated blood products are transfused into recipients, leading to viral or bacterial transmission. In regions with high disease prevalence, inadequate blood screening protocols and limited access to safe blood products contribute to the risk of TTIs, highlighting the importance of stringent blood safety measures. Hemolytic reactions can occur due to ABO incompatibility, alloimmunization, or other factors, leading to hemolysis and associated complications such as hemolytic transfusion reactions and delayed hemolytic transfusion reactions. Pediatric patients with underlying hematological disorders are particularly susceptible to alloimmunization due to repeated transfusions, increasing their risk of hemolytic reactions and complicating subsequent transfusion therapy. Fluid overload is another common complication of blood transfusion, particularly in pediatric patients with underlying cardiac or renal dysfunction. Excessive transfusion volume can lead to volume overload, pulmonary edema, and cardiac decompensation, necessitating careful monitoring and adjustment of transfusion volume to prevent complications.<sup>61-90</sup>

### **Clinical Manifestations and Management**

Transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders can manifest with a diverse range of clinical symptoms, necessitating vigilant monitoring and prompt intervention to optimize patient outcomes. Clinical manifestations may vary depending on the type and severity of the complication and the underlying health status of the patient. Transfusion-transmitted infections (TTIs) can present with a wide range of clinical symptoms, including fever, fatigue, jaundice, and hepatomegaly. In pediatric patients with severe malaria and HIV infection, the clinical presentation of TTIs may overlap with symptoms of the underlying diseases, making diagnosis challenging. Early recognition of TTIs is crucial for initiating appropriate treatment and preventing further transmission to other patients and healthcare workers. Hemolytic reactions, including acute hemolytic transfusion reactions (AHTRs) and delayed hemolytic transfusion reactions (DHTRs), can present with symptoms such as fever, chills, back pain, hemoglobinuria, and hemodynamic instability. In children with underlying hematological disorders, alloimmunization may further complicate hemolytic reactions, requiring specialized management strategies such as phenotypically matched blood transfusions and immunosuppressive therapy.<sup>91-110</sup>

Fluid overload is another common complication of blood transfusion, particularly in pediatric patients with underlying cardiac or renal dysfunction. Symptoms of fluid overload may include dyspnea, tachypnea, cough, orthopnea, and edema. Close monitoring of fluid balance and hemodynamic parameters is essential for early detection and management of fluid overload, with interventions such as diuretic therapy and oxygen supplementation as necessary. Management of

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. Elite Journal of Medical Sciences, 2024; 2(4):1-20

transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders requires a multidisciplinary approach involving healthcare providers from various specialties, including infectious diseases, hematology, transfusion medicine, and critical care. Prompt recognition and intervention are essential for minimizing morbidity and mortality and optimizing patient outcomes. Strategies for managing transfusion-related complications may include discontinuation of transfusion, supportive care, pharmacological interventions, and, in severe cases, advanced life support measures such as mechanical ventilation and vasopressor therapy. Healthcare providers must also address underlying risk factors and comorbidities to prevent recurrent complications and improve long-term outcomes.<sup>111-130</sup>

### Challenges and Future Directions

Despite advances in transfusion medicine, several challenges persist in managing transfusion-related complications in children with severe malaria, HIV infection, and underlying hematological disorders. Limited access to safe blood products, inadequate healthcare infrastructure, and resource constraints in low-resource settings hinder optimal transfusion practices. In regions with high disease burden, such as sub-Saharan Africa, blood shortages, inadequate screening protocols, and lack of trained personnel contribute to the risk of transfusion-related infections and other complications. Furthermore, the complex pathophysiological interactions between severe malaria, HIV infection, and hematological disorders necessitate tailored approaches to transfusion therapy, further complicating clinical decision-making. Pediatric patients with severe malaria and HIV infection may have compromised immune systems, increasing their susceptibility to transfusion-related infections and other adverse events. Similarly, children with underlying hematological disorders may require specialized transfusion protocols and additional monitoring to prevent complications such as iron overload and alloimmunization.

Addressing these challenges requires a multifaceted approach that encompasses improvements in blood safety measures, healthcare infrastructure, and transfusion protocols. Investments in blood screening technologies, such as nucleic acid amplification testing (NAT), can enhance the detection of transfusion-transmitted infections and reduce the risk of transmission in pediatric patients. Additionally, strengthening healthcare systems, training healthcare personnel, and implementing standardized transfusion protocols are essential for ensuring safe and effective transfusion practices in resource-limited settings. Future research should focus on developing alternative treatment modalities and transfusion strategies for pediatric patients with severe malaria, HIV infection, and underlying hematological disorders. Advances in transfusion medicine, such as the development of synthetic blood substitutes and non-transfusion therapies for managing anemia, may offer alternative approaches to traditional blood transfusion in this population. Furthermore, prospective studies are needed to assess the long-term safety and efficacy of transfusion therapy in children with complex hematological conditions, including its impact on disease progression, neurocognitive development, and quality of life.<sup>131-194</sup>

### Conclusion

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. Elite Journal of Medical Sciences, 2024; 2(4):1-20

Transfusion-related complications pose significant challenges in the management of pediatric patients with severe malaria, HIV infection, and underlying hematological disorders. Despite advances in transfusion medicine, limited access to safe blood products, inadequate healthcare infrastructure, and complex pathophysiological interactions continue to hinder optimal transfusion practices in resource-limited settings. However, by addressing these challenges and investing in research, training, and infrastructure development, healthcare providers can improve transfusion practices and optimize outcomes for this vulnerable population.

Multifaceted approaches, including improvements in blood safety measures, healthcare infrastructure, and transfusion protocols, are needed to mitigate transfusion-related risks and enhance patient safety. Investments in blood screening technologies, healthcare systems strengthening, and standardized transfusion protocols are essential for ensuring safe and effective transfusion practices in regions with high disease burden. Additionally, advancements in transfusion medicine, such as the development of alternative treatment modalities and non-transfusion therapies, hold promise for reducing reliance on traditional blood transfusion in pediatric patients with complex hematological conditions.

## References

1. Alonso PL, Tanner M. Public health challenges and prospects for malaria control and elimination. *Nature medicine*. 2013;19(2):150-155.
2. Muhammad F, Abdulkareem JH, Chowdhury AA. Major public health problems in Nigeria: a review. *South East Asia Journal of Public Health*. 2017;7(1):6-11.
3. González R, Ataíde R, Naniche D, Menéndez C, Mayor A. HIV and malaria interactions: where do we stand? Expert review of anti-infective therapy. 2012 Feb 1;10(2):153-65.
4. De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. *The Pediatric infectious disease journal*. 2007;26(2):163-173.
5. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution, and interventions for infectious diseases of poverty. *Infectious diseases of poverty*. 2014; 3:1-7.
6. Crawley J, Chu C, Mtove G, Nosten F. Malaria in children. *The Lancet*. 2010;375(9724):1468-1481.
7. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(2):1-9.
8. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.
9. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine*. 2023;102(46): e36166.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

10. Obeagu EI, Chijioke UO, Ekelozie IS. Malaria rapid diagnostic test (RDTs). *Ann Clin Lab Res.* 2018;6(4):275.
11. Ogomaka IA, Obeagu EI. Methods of Breast Feeding as Determinants of Malaria Infections among Babies in IMO State, Nigeria. *International Journal of Medical Science and Dental Research.* 2019;2(01):17-24.
12. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):33-45.
13. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):33-45.
14. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine.* 2024;2(1):10-22.
15. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology.* 2024;2(1):26-41.
16. Obeagu EI, Babar Q, Obeagu GU. Allergic blood Transfusion reaction: A Review. *Int. J. Curr. Res. Med. Sci.* 2021;7(5):25-33.
17. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):120-127.
18. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
19. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri.* 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
20. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19.
21. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci.* 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
22. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
23. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20



- Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
24. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
  25. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
  26. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.5923/bb.4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf).
  27. Obeagu EI, Obeagu GU, Egba SI, Emeka-Obi OR. Combatting Anemia in Pediatric Malaria: Effective Management Strategies. *Int. J. Curr. Res. Med. Sci*. 2023;9(11):1-7.
  28. Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria Vaccine: Prospects and Challenges. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(2):22-40.
  29. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
  30. Obeagu EI, Busari AI, Uduchi IO, Ogomaka IA, Ibekwe AM, Vincent CC, Chijioke UO, Okafor CJ, Okoroiwu HU, Adike CN. Age-Related Haematological Variations in Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(42B):218-24.
  31. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(41B):380-386.
  32. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):26-35.
  33. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
  34. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
  35. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
  36. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-37.
  37. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

- 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
38. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
  39. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.iosrjournals.org/ViewFullText.aspx?doi=10.21961/iosrjps.120407)
  40. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
  41. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDA-AND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311111111_CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDA-AND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA).
  42. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144. [https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJCRRAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf).
  43. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/328111111_Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe)
  44. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
  45. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
  46. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20



[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).

47. Obeagu EI, Babar Q, Uduchi IO, Ibekwe AM, Chijioke UO, Okafor CJ, Vincent CC. An Update on Transfusion Related Immunomodulation (TRIM) in a Time of COVID-19 Pandemic. *Journal of Pharmaceutical Research International*. 2021;33(42A):135-146.
48. Okoroiwu IL, Obeagu EI, Elemchukwu Q, Ochei KC, Christian GS. Frequency of Transfusion Reactions Following Compatible Cross Matching of Blood: A Study in Owerri Metropolis. *International Journal of Current Research and Academic Review*. 2015;3(1):155-160.
49. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. *Int. J. Curr. Res. Med. Sci*. 2016;2(10):16-48.
50. Ogar CO, Okoroiwu HU, Obeagu EI, Etura JE, Abunimye DA. Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. *Transfusion Clinique et Biologique*. 2021;28(1):68-72.
51. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine*. 2023;102(47): e36342.
52. Ogbonna CO, Obeagu EI, Ufelle SA, Ogbonna LN. Evaluation of haematological alterations in children infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(1):38-45.
53. Okorie HM, Obeagu EI, Obarezi HC, Anyiam AF. Assessment of some inflammatory cytokines in malaria infected pregnant women in Imo State Nigeria. *International Journal of Medical Science and Dental Research*. 2019;2(1):25-36.
54. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
55. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int. J. Curr. Res. Biol. Med*. 2018;3(9):1-4.
56. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with Plasmodium falciparum malaria in Owerri municipal council of Imo state. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2016;3(8):40-46.
57. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):128-134.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
58. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022:29-34.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

59. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
60. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137.  
[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
61. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
62. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
63. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014  
[https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfectd with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf)
64. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
65. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137  
[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137).
66. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

67. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. *EC Emergency Medicine and Critical Care*. 2020;4(7):33-40.
68. Obeagu EI, Buhari HA. Implications of Blood Transfusion in Renal Disease Patients. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(10):45-49.
69. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. *Asian Hematology Research Journal*. 2022;6(3):9-17.
70. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024;103(2): e36937.
71. Obeagu EI. An update on susceptibility of individuals to diseases based on ABO blood groups. *Int. J. Curr. Res. Med. Sci.* 2019;5(3):1-8.
72. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206.
73. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. *Asian Hematology Research Journal*. 2022;6(3):9-17.
74. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.
75. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by *Plasmodium falciparum* Species in Enugu, Enugu State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(15):1-8.
76. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences*. 2018;4(9):41-9.
77. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-211.  
<http://research.sdpublishers.net/id/eprint/2819/>.
78. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
79. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

80. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
81. Nwosu DC, Nwanjo HU, Okolie NJ, Ikech K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpr.in/index.php/wjpr/article/view/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
82. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
83. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: 10.22192/ijcreps.2019.06.12.004  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/index.php/ijcreps/article/view/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
84. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/index.php/ijcrms/article/view/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
85. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508acebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/index.php/ijcrms/article/view/links/5711c47508acebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
86. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.  
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
87. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
88. Ibebuikwe JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

89. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci*. 2014; 5:825-830.
90. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharmacy Research*. 2014; 391:186-189.
91. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
92. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
93. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomesine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
94. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
95. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
96. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
97. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
98. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
99. Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. *European journal of paediatric neurology*. 2007;11(1):1-9.
100. Trivedi S, Chakravarty A. Neurological complications of malaria. *Current neurology and neuroscience reports*. 2022;22(8):499-513.
101. Eze R, Obeagu EI, Nwakulite A, Vincent CC, Ogbodo SO, Ibekwe AM, Okafor CJ, Chukwurah EF. Frequency of Haemoglobin Genotype Variants, ABO and Rh 'D' Antigen among Madonna Undergraduates of South East Origin, Nigeria. *Journal of Pharmaceutical Research International*. 2021 May 26;33(29B):149-57.
102. Okoroiwu IL, Obeagu EI, Christian SG, Elemchukwu Q, Ochei KC. Determination of the haemoglobin, genotype and ABO blood group pattern of some students of Imo State

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20



- University, Owerri, Nigeria. *International Journal of Current Research and Academic Review*. 2015;3(1):20-27.
103. Oloro OH, Obeagu EI, Puche RO, Lawal OA. Blood Products in Blood Banking: Preparation and Clinical Importance. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(3):102-109.
  104. Asemota EA, Njar VE, Aguanah IT, Obeagu EI. Distribution of ABO, Rhesus Blood Group and Helicobacter Pylori Infection among Secondary School Students in Calabar South Local Government, Cross River State, Nigeria. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2023;3(1):32-45.
  105. Obeagu EI, Katya MC. A Systematic Review on Physiological Jaundice: Diagnosis and Management of the Affected Neonates. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):25-41.
  106. Ogbonna LN, Ezeoru VC, Ofodile AC, Ochiabuto OM, Obi-Ezeani CN, Okpala PU, Okafor CJ, Obeagu GU, Busari AI, Obeagu EI. Gender Based Variations of Haematological Parameters of Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(8):75-80.
  107. Eberendu IF, Ozims SJ, Agu GC, Amah HC, Obasi CC, Obioma-Elemba JE, Ihekaire DE, Ibanga IE, Amah CC, Obeagu EI, Nwosu DC. Impact of human activities on the breeding of mosquitoes of human disease in Owerri metropolis, Imo state. *Int J Adv Res Biol Sci IJARBS*. 2017;4(12):98-106.
  108. Obeagu EI, Ofodile AC, Okwuanaso CB. A review on socio economic and behavioral aspects of malaria and its control among children under 5 years of age in Africa. *J Pub Health Nutri*. 2023; 6 (1): 136.
  109. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
  110. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
  111. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
  112. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
  113. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

114. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
115. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
116. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
117. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
118. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
119. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
120. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.
121. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):46-58.
122. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine.* 2024;2(1):35-46.
123. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;*12(01).
124. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV.* 2024;2(1):65-78.
125. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;*12(01).
126. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV.* 2024;2(1):31-50.
127. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV.* 2024;2(1):1-5.
128. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
129. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences.* 2024;4(1):32-7.
130. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences.* 2024;4(1):38-44.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

131. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
132. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
133. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
134. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
135. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
136. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
137. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
138. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
139. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
140. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
141. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
142. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
143. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
144. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
145. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
146. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

147. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
148. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
149. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
150. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
151. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
152. Obeagu EI, Amaeze AA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
153. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
154. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
155. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
156. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
157. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijar.com>;12(01)*.
158. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;12(01)*.
159. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
160. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
161. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

162. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
163. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
164. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
165. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
166. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
167. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
168. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
169. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
170. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
171. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
172. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
173. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
174. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
175. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
176. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
177. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
178. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-5.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20



179. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.
180. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
181. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
182. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
183. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
184. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
185. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
186. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
187. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
188. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
189. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
190. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
191. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
192. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
193. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. *Elite Journal of Medical Sciences*, 2024; 2(4):1-20

194. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3):111-7.

**Citation:** Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children with Severe Malaria, HIV, and Underlying Hematological Disorders: A Review. Elite Journal of Medical Sciences, 2024; 2(4):1-20